Last reviewed · How we verify
Fluad alone
Fluad is an inactivated influenza vaccine adjuvanted with MF59 that enhances immune response to seasonal influenza strains.
Fluad is an inactivated influenza vaccine adjuvanted with MF59 that enhances immune response to seasonal influenza strains. Used for Seasonal influenza prevention in adults aged 65 years and older, Seasonal influenza prevention in adults at high risk of complications.
At a glance
| Generic name | Fluad alone |
|---|---|
| Sponsor | Korea University Guro Hospital |
| Drug class | Inactivated influenza vaccine with adjuvant |
| Target | Influenza virus hemagglutinin and neuraminidase antigens; MF59 acts as immunological adjuvant |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Fluad contains inactivated influenza virus antigens combined with the MF59 oil-in-water emulsion adjuvant, which amplifies the body's adaptive immune response to the vaccine antigens. The adjuvant stimulates innate immunity and increases antibody production and cellular immune responses compared to non-adjuvanted influenza vaccines. This formulation is particularly designed to improve immunogenicity in older adults and other populations with potentially weaker immune responses.
Approved indications
- Seasonal influenza prevention in adults aged 65 years and older
- Seasonal influenza prevention in adults at high risk of complications
Common side effects
- Injection site reactions (pain, erythema, swelling)
- Myalgia
- Headache
- Fatigue
- Fever
Key clinical trials
- A Study of Modified mRNA Vaccines in Healthy Adults (PHASE1)
- WU 345: Immune Responses to Adjuvanted and Non-adjuvanted Seasonal Influenza Vaccines in the Lymphoid Tissues. (EARLY_PHASE1)
- A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults (PHASE2)
- B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults (PHASE4)
- Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP (PHASE3)
- A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above (PHASE3)
- FLUAD vs. FLUZONE HD Influenza Vaccine in Residents of Long Term Care (PHASE4)
- Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |